Table 1 Patients characteristics
Characteristics | THA | TKA | p | ||
|---|---|---|---|---|---|
n = 214 | n = 160 | ||||
Age | 65.6 ± 11.7 | (25-90) | 73.9 ± 8.9 | (30-89) | <0.00001 |
   Age≧75 yr | 49 | 89 | <0.00001 | ||
   Age < 75 yr | 165 | 71 | |||
Gender(male/female) | 34/180 | 31/129 | 0.379 | ||
BMI(Kg/m2) | 24.1 ± 3.8 | (15.1-37.7) | 25.9 ± 4.3 | (13.7-41.4) | <0.00001 |
   BMI≧30 | 17 | 30 | 0.002 | ||
   BMI < 30 | 197 | 130 | |||
Risk factors | 102/214 | (47.7%) | 112/160 | (70.0%) | <0.00001 |
OA/RA | 192/22 | 129/31 | 0.013 | ||
Seroconvertion of IgG-class Anti-PF4/heparinAb | 30/214 | (14.0%) | 44/160 | (27.5%) | 0.001 |
Treatment | |||||
   UFH | 60/214 | (28.0%) | 44/160 | (27.5%) | 0.909 |
   LMWH | 64/214 | (29.9%) | 31/160 | (19.4%) | 0.021 |
   Fondaparinux | 49/214 | (22.9%) | 32/160 | (20.0%) | 0.501 |
   Others | 21/214 | (9.8%) | 29/160 | (18.1%) | 0.019 |
Aspirin | 16/214 | (7.5%) | 27/160 | (16.9%) | |
Warfarin | 4/214 | (1.9%) | 1/160 | (0.6%) | |
Cilostazol | 14/214 | (6.5%) | 23/160 | (14.4%) | |
   No medication | 20/214 | (9.3%) | 24/160 | (15.0%) | 0.093 |